Sorafenib to prevent relapse after stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether the drug sorafenib can prevent blood cancer from returning after a stem cell transplant. It is for people who had a special combination of chemotherapy (bendamustine and cyclophosphamide) during their transplant and are at high risk for relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a stem cell transplant that included the drugs bendamustine and cyclophosphamide.
- You have a high-risk blood cancer, such as acute myeloid leukemia that wasn't in remission before transplant, or certain genetic subtypes.
- A bone marrow test after transplant shows your cancer is in remission, even if a tiny amount is still detectable.
- You are within the first 100 days after your transplant.
- Your cancer has not come back after the transplant and been treated.
- Your heart, lungs, liver, and kidneys are working well enough, and you do not have serious infections or other health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two chemotherapy drugs (bendamustine and cyclophosphamide) given before a stem cell transplant to help prevent graft-versus-host disease. It is for people with high-risk blood cancers who don't have a fully matched donor and will receive a partially matched transplant.
This trial tests whether the drug interferon alfa can help prevent blood cancer from coming back after a stem cell transplant. It is for people with certain types of blood cancer (MDS or AML with a TP53 mutation) who had no detectable cancer cells when checked after transplant.
This trial checks if using advanced tests to find leftover cancer cells before a stem cell transplant can help prevent the disease from coming back. If you have a myeloid blood cancer, you might be able to join.
This trial tests if combining sorafenib and venetoclax can help people with acute myeloid leukemia (AML) who still have minimal residual disease (MRD) after treatment. The goal is to prevent the leukemia from coming back.
This trial tests whether giving medication after a donor stem cell transplant can prevent the return of very high-risk myelodysplastic syndrome (MDS). It is for people who have a suitable donor and are healthy enough for the procedure.
This trial tests two maintenance drugs (gilteritini and sorafenib) for people with FLT3-ITD positive AML after a stem cell transplant. It compares which drug better prevents relapse using a sensitive test for minimal residual disease (MRD).
Hear when a new Acute Myeloid Leukemia, in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.